The structural barrier of absorptive mucosae: site difference of the permeability of fluorescein isothiocyanate-labelled dextran in rabbits - PubMed

The structural barrier of absorptive mucosae: site difference of the permeability of fluorescein isothiocyanate-labelled dextran in rabbits

K Hosoya et al. Biopharm Drug Dispos. 1993 Nov.

Abstract

The permeability of fluorescein isothiocyanate-labelled dextran (FD, M.W. 4400-71,200) across nasal, buccal, duodenal, jejunal, ileal, colonic, and rectal mucosae excised from rabbits has been measured to estimate the structural barrier of absorptive mucosae using Ussing-type diffusion chambers. The permeability coefficient of FD in all these mucosae decreased with increasing molecular weight. The rank order of FD permeability did not always correlate with the electrical resistance of the mucosae. Among components of the small intestine (duodenum, jejunum, ileum) and the large intestine (colon, rectum), however, the rank order of FD permeability corresponded to the magnitude of the electrical resistance in each instance; the upper colonic mucosa showed the highest permeability, especially in FD of low molecular weight, and permeability of the rectal mucosa was lowest except for the duodenal mucosa. The nasal mucosa showed the lowest electrical resistance and the highest permeability of those studied, suggesting that it has a leaky structural barrier.

Similar articles

• Effect of sodium taurodihydrofusidate on nasal drug delivery: differences in its concentration and penetrant molecular weight.

  Hosoya K, Kubo H, Akutsu T, Natsume H, Sugibayashi K, Morimoto Y. Hosoya K, et al. Arch Pharm Res. 1994 Apr;17(2):57-9. doi: 10.1007/BF02974223. Arch Pharm Res. 1994. PMID: 10319131

• Labrafac^TM MC60 is an efficacious intestinal permeation enhancer for macromolecules: Comparisons with Labrasol® ALF in ex vivo and in vivo rat studies.

  McCartney F, Caisse P, Dumont C, Brayden DJ. McCartney F, et al. Int J Pharm. 2024 Aug 15;661:124353. doi: 10.1016/j.ijpharm.2024.124353. Epub 2024 Jun 22. Int J Pharm. 2024. PMID: 38909926

• Evaluation of enhancers to increase nasal absorption using Ussing chamber technique.

  Hosoya K, Kubo H, Natsume H, Sugibayashi K, Morimoto Y. Hosoya K, et al. Biol Pharm Bull. 1994 Feb;17(2):316-22. doi: 10.1248/bpb.17.316. Biol Pharm Bull. 1994. PMID: 7515747

• Human vaginal mucosa as a model of buccal mucosa for in vitro permeability studies: an overview.

  van der Bijl P, van Eyk AD. van der Bijl P, et al. Curr Drug Deliv. 2004 Apr;1(2):129-35. doi: 10.2174/1567201043479975. Curr Drug Deliv. 2004. PMID: 16305378 Review.

• We may not measure the correct intestinal wall permeability coefficient of drugs: alternative absorptive clearance concept.

  Chiou WL. Chiou WL. J Pharmacokinet Biopharm. 1995 Jun;23(3):323-31. doi: 10.1007/BF02354288. J Pharmacokinet Biopharm. 1995. PMID: 8834199 Review.

Cited by

• Confocal laser scanning microscopic visualization of the transport of dextrans after nasal administration to rats: effects of absorption enhancers.

  Marttin E, Verhoef JC, Cullander C, Romeijn SG, Nagelkerke JF, Merkus FW. Marttin E, et al. Pharm Res. 1997 May;14(5):631-7. doi: 10.1023/a:1012109329631. Pharm Res. 1997. PMID: 9165535

• Development of In Vitro Evaluation System for Assessing Drug Dissolution Considering Physiological Environment in Nasal Cavity.

  Inoue D, Yamashita A, To H. Inoue D, et al. Pharmaceutics. 2022 Oct 31;14(11):2350. doi: 10.3390/pharmaceutics14112350. Pharmaceutics. 2022. PMID: 36365167 Free PMC article.

• The characterization of the human nasal epithelial cell line RPMI 2650 under different culture conditions and their optimization for an appropriate in vitro nasal model.

  Kreft ME, Jerman UD, Lasič E, Lanišnik Rižner T, Hevir-Kene N, Peternel L, Kristan K. Kreft ME, et al. Pharm Res. 2015 Feb;32(2):665-79. doi: 10.1007/s11095-014-1494-0. Epub 2014 Aug 22. Pharm Res. 2015. PMID: 25145337

• Spanlastics as a Potential Platform for Enhancing the Brain Delivery of Flibanserin: In Vitro Response-Surface Optimization and In Vivo Pharmacokinetics Assessment.

  Alharbi WS, Hareeri RH, Bazuhair M, Alfaleh MA, Alhakamy NA, Fahmy UA, Alamoudi AA, Badr-Eldin SM, Ahmed OA, AlGhamdi SA, Naguib MJ. Alharbi WS, et al. Pharmaceutics. 2022 Nov 28;14(12):2627. doi: 10.3390/pharmaceutics14122627. Pharmaceutics. 2022. PMID: 36559120 Free PMC article.

• Improved Intranasal Retentivity and Transnasal Absorption Enhancement by PEGylated Poly-l-ornithine.

  Kamiya Y, Yamaki T, Omori S, Uchida M, Ohtake K, Kimura M, Yamazaki H, Natsume H. Kamiya Y, et al. Pharmaceuticals (Basel). 2018 Jan 25;11(1):9. doi: 10.3390/ph11010009. Pharmaceuticals (Basel). 2018. PMID: 29370117 Free PMC article.

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Wiley

• Other Literature Sources

  • The Lens - Patent Citations Database